Drug discovery is in the midst of one of the most consequential transformations in its history, and a sweeping special issue of the journal Molecular Diversity, published in September 2026, captures the scale of that change. Guest edited by Taoda Shi of Sun Yat-sen University in Guangzhou, the collection brings together 58 articles that map how innovative synthetic chemistry, emerging therapeutic modalities, advanced screening technologies, and data-driven approaches are converging to reshape the way medicines are found. The stated ambition of the issue was to highlight technologies that expand accessible chemical space, uncover new biological mechanisms, and accelerate the translation of molecular design into therapeutic validation. What the assembled papers demonstrate, taken together, is that no single platform defines the current revolution. Instead, progress is emerging from the deliberate integration of chemistry, biology, computation, and pharmacology into unified discovery workflows.
The original call for papers read like a catalogue of the field’s hottest frontiers: targeted protein degradation, molecular glues, covalent inhibitors, antibody-drug conjugates, macrocycles, nucleoside therapeutics, immuno-oncology agents, natural-product discovery, multicomponent reactions, advanced imaging and screening technologies, and artificial intelligence. That breadth is significant in itself. A decade ago, many of these approaches were considered speculative or confined to a handful of specialist laboratories. Today they constitute a mainstream toolkit, and the 58 accepted articles show researchers across medicinal chemistry, chemical biology, and pharmacology routinely combining them rather than working in silos. The result, according to the editorial framing the collection, is a discovery enterprise that is faster, more efficient, and increasingly sophisticated in how it approaches molecular design.
A central theme running through the issue is the development of efficient and diversity-oriented synthetic strategies for bioactive molecules. The published articles describe asymmetric and visible-light-promoted reactions, multicomponent and one-pot syntheses, iron-catalyzed functionalization, nanocatalytic and sonochemical methods, skeletal editing, total synthesis, and optimized synthetic routes. Each of these techniques addresses a persistent bottleneck in drug discovery: the speed and reliability with which chemists can actually make the molecules that computational and biological studies suggest might work. Visible-light photocatalysis, for example, allows bond formations under mild conditions that were previously difficult or impossible, while skeletal editing permits late-stage modifications of molecular frameworks that would once have required rebuilding a candidate from scratch. Multicomponent reactions compress multi-step sequences into single operations, dramatically shortening the path from idea to testable compound.
Crucially, the synthetic advances described in the collection are not presented as ends in themselves. The resulting compounds, which include diverse indoles, indolizines, heterocycles, molecular hybrids, peptides, and natural-product analogues with enhanced structural and stereochemical complexity, were investigated as anticancer, antimicrobial, antitubercular, antiviral, anti-inflammatory, antidiabetic, antiseizure, and neuroprotective agents. This direct linkage between methodology and biological application is what distinguishes the current wave of synthetic innovation from earlier eras in which method development and drug hunting often proceeded on separate tracks. When a new catalytic reaction can be evaluated within weeks against disease-relevant cell models, the feedback loop between chemistry and pharmacology tightens, and the odds that an interesting molecule becomes a therapeutic candidate improve accordingly.
Another striking pattern in the collection is the continuing shift beyond the traditional one drug-one target paradigm that dominated pharmaceutical research for much of the past half-century. Among the highlighted examples are dual inhibitors targeting BTK/FLT3, COX-2/5-LOX, and FAAH/sEH, enzyme pairs relevant to cancer and inflammation, alongside multifunctional agents designed for Alzheimer’s disease and reviews of xanthone hybrids and pyrazolopyrimidine-based dual inhibitors. Multi-target design acknowledges that complex diseases rarely hinge on a single protein, and that modulating several nodes of a pathological network simultaneously can be more effective than maximal blockade of one. The approach demands a different kind of medicinal chemistry, one in which selectivity is engineered across multiple binding sites rather than maximized against a single target, and the articles in the issue show that scaffold design and mechanistic understanding are being integrated to meet exactly that challenge.
The issue also surveys work on established and emerging molecular targets, including FAK, HDAC, ERα, PI3Kδ, p38 MAPK, EZH2, DprE1, histamine H1 and H2 receptors, SFRP1, PDE4B, and nitric oxide synthase. This list spans kinases, epigenetic enzymes, nuclear receptors, phosphodiesterases, and bacterial cell-wall biosynthesis machinery, reflecting the wide biological terrain on which modern medicinal chemistry now operates. A dedicated review on PROTAC technology underscores the prominence of targeted protein degradation, one of the most promising new therapeutic modalities of the past decade. Rather than inhibiting a protein’s activity, degraders recruit cellular disposal machinery to eliminate the disease-causing protein altogether, an approach that can succeed against targets long considered undruggable by conventional small molecules. Its inclusion alongside classical target families illustrates how new modalities are being folded into, rather than replacing, the existing discovery apparatus.
Natural products and biomolecule-inspired scaffolds remain a major focus of the collection, and the evidence assembled suggests that nature is far from exhausted as a source of molecular diversity. Studies on phorbazole D, menominin A, polyprenylated acylphloroglucinols, oleanolic and alepterolic acids, Eucommiae folium, µ-conotoxins, honey-bee antimicrobial peptides, and marine cyclopeptides demonstrate the remarkable chemical inventiveness of the natural world, from terrestrial plants to venomous cone snails and social insects. What has changed is the technology brought to bear on these molecules. Total synthesis, analogue generation, chemical ligation, mass spectrometry, network pharmacology, and cell-based screening are overcoming longstanding challenges in natural-product discovery and optimization, problems of supply, structural complexity, and limited optimization potential that historically kept many natural products out of the clinic despite compelling biological activity.
The synergy between computation and experimentation emerges as perhaps the defining feature of the modern discovery pipeline. Molecular docking, molecular dynamics simulations, pharmacophore modeling, network pharmacology, and integrated in silico-in vitro workflows now support compound prioritization and mechanistic studies across the collection. These are not decorative additions; they determine which of millions of conceivable molecules get synthesized and tested, effectively allocating scarce laboratory resources. AI-assisted analysis, label-free cell-based screening, high-resolution LC-Orbitrap mass spectrometry, and zebrafish disease models further illustrate advances in compound characterization, phenotypic screening, and translational validation. Phenotypic screening in whole organisms such as zebrafish is particularly notable, because it allows compounds to be evaluated for efficacy and toxicity in a living system before the costly transition to mammalian models, catching failures earlier and more cheaply than traditional pipelines allow.
The collective message of the 58 articles is that new technologies in drug discovery are not defined by any single platform or methodology, but by the integration of innovative chemistry, emerging therapeutic modalities, computational prediction, advanced screening technologies, and rigorous biological validation. This multidisciplinary convergence is expanding druggable chemical space, the universe of molecules that can realistically be made, characterized, and developed into medicines, while accelerating therapeutic discovery and enabling increasingly sophisticated approaches to drug design. For decades, the pharmaceutical industry has grappled with declining productivity per research dollar, and collections like this one suggest a credible path forward: rather than betting on any single breakthrough, the field is stacking multiple incremental advantages in synthesis, target biology, computation, and screening into compounding gains across the entire pipeline.
In closing the special issue, Shi thanks the authors, reviewers, and the editorial team of Molecular Diversity, and expresses the hope that the collection will stimulate new collaborations, inspire continued technological innovation, and contribute to making drug discovery faster, more efficient, and more successful while preserving the molecular and mechanistic diversity that underpins transformative medicines. That emphasis on diversity is more than rhetorical. History shows that transformative drugs often emerge from unexpected chemical territory, and the deliberate cultivation of varied scaffolds, modalities, and screening strategies is the best insurance against the field narrowing prematurely around fashionable targets. If the technologies surveyed here continue to mature and interconnect, the coming decade of drug discovery may look markedly different from the last, with molecules designed, synthesized, and validated at a pace and precision that earlier generations of researchers could scarcely have imagined.
Subject of Research: Emerging technologies and multidisciplinary approaches in drug discovery
Article Title: New technologies in drug discovery
Article References: Shi, T. (2026). New technologies in drug discovery. Molecular Diversity. https://doi.org/10.1007/s11030-026-11711-2
Image Credits: AI Generated
DOI: 10.1007/s11030-026-11711-2
Keywords: drug discovery, medicinal chemistry, targeted protein degradation, PROTAC, molecular glues, natural products, artificial intelligence, multicomponent reactions, phenotypic screening, dual inhibitors, chemical biology, Molecular Diversity
Cite Scienmag News
APA
MLA
Chicago
Louis Brooks. (September 25, 2026). From Molecular Glues to AI: The Technologies Reshaping Drug Discovery. Scienmag. https://scienmag.com/from-molecular-glues-to-ai-the-technologies-reshaping-drug-discovery/
Louis Brooks. “From Molecular Glues to AI: The Technologies Reshaping Drug Discovery.” Scienmag, 25 September 2026, https://scienmag.com/from-molecular-glues-to-ai-the-technologies-reshaping-drug-discovery/. Accessed 25 September 2026.
Louis Brooks. “From Molecular Glues to AI: The Technologies Reshaping Drug Discovery.” Scienmag. September 25, 2026. https://scienmag.com/from-molecular-glues-to-ai-the-technologies-reshaping-drug-discovery/
Copy citation
Download RIS
Tags: advanced screening technologies in medicineAI-driven drug discoveryArtificial Intelligenceartificial intelligence applications in molecular designchemical biologycomputational approaches in pharmacologydrug discoverydrug discovery innovationdual inhibitorsintegration of chemistry and biology in drug researchmedicinal chemistryMolecular Diversitymolecular gluesmolecular glues in therapeuticsmulticomponent reactionsmulticomponent reactions in pharmaceuticalsnatural product discovery techniquesnatural productsnew modalities in cancer treatmentphenotypic screeningPROTACsynthetic chemistry for drug developmenttargeted protein degradationtargeted protein degradation strategies
